Item List

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 Gene Therapy in Adults with Macular Neovascularization

A Phase 3 Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients with Geographic Atrophy (GA)

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

CAPRI: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME (DME)
To be eligible for the study, participants must be at least 18 years of age or older, have been diagnosed with Type 1/2 Diabetes and DME associated with Diabetic Retinopathy, and willing to allow Aqueous Humor collection

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/​Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneration

A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World
Safety, Tolerability and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with
Geographic Atrophy Secondary to Age-Related Macular Degeneration

Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related

Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of oral BI 1584862

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56 (wAMD)
To be eligible for the study, participants must be at least 50 years of age or older, have been diagnosed with wAMD, and have received previous eye injection treatments for wAMD.

The Natural History Observation Registry (NHOR) is a world-wide registry of individuals with Macular Telangiectasia type 2, and their family members.

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participation with Diabetic Macular Edema